콘텐츠로 건너뛰기
Merck

910066

6-(2-(2-(Oct-7-yn-1-yloxy)ethoxy)ethoxy)hexanoic acid

≥90%

동의어(들):

6-2-2-6 PROTAC® linker, Alkyne-PEG3-acid, Bifunctional linker

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C18H32O5
Molecular Weight:
328.44
UNSPSC Code:
12352106
Assay:
≥90%
Form:
liquid
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


assay

≥90%

form

liquid

reaction suitability

reagent type: linker

functional group

alkyne, carboxylic acid

storage temp.

2-8°C

SMILES string

OC(CCCCCOCCOCCOCCCCCCC#C)=O

Application

This heterobifunctional, PEGylated crosslinker 6-(2-(2-(oct-7-yn-1-yloxy)ethoxy)ethoxy)hexanoic acid features a carboxyl group at one end and an alkyne at the other and exhibits both hydrophobic and hydrophilic moieties for use in biological applications. This alkyne-PEG3-acid linker can be used for bioconjugation or as a building block for synthesis of small molecules, conjugates of small molecules and/or biomolecules, or other tool compounds for chemical biology and medicinal chemistry that require ligation. Examples of applications include its synthetic incorporation into antibody-drug conjugates or proteolysis-targeting chimeras (PROTAC® molecules) for targeted protein degradation where the linker region is referred to as 6-2-2-6.

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license


저장 등급

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문



Ashton C Lai et al.
Angewandte Chemie (International ed. in English), 55(2), 807-810 (2015-11-26)
Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs. PROTAC technology employs small molecules that recruit target proteins for ubiquitination and